REFERENCES
1. Vemulapalli S, Carroll JD, Mack MJ, et al. Procedural volume and outcomes for transcatheter aortic-valve replacement. N Engl J Med 2019;380:2541-50.
2. Dvir D, Webb JG, Bleiziffer S, et al. Valve-in-Valve International Data Registry Investigators. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162-70.
3. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol 2020;76:2492-516.
4. Webb JG, Murdoch DJ, Alu MC, et al. 3-year outcomes after valve-in-valve transcatheter aortic valve replacement for degenerated bioprostheses: the PARTNER 2 registry. J Am Coll Cardiol 2019;73:2647-55.
5. Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 2017;38:3382-90.
6. Généreux P, Piazza N, Alu MC, et al. VARC-3 Writing Committee. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol 2021;77:2717-46.
7. Otto CM, Nishimura RA, Bonow RO, et al. Writing Committee Members. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:450-500.
8. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention 2022;17:e1126-96.
9. Sá MPBO, Van den Eynde J, Simonato M, et al. Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve replacement: an updated meta-analysis. JACC Cardiovasc Interv 2021;14:211-20.
10. Thandra A, Abusnina W, Jhand A, et al. Valve-in-valve transcatheter aortic valve replacement versus redo surgical valve replacement for degenerated bioprosthetic aortic valve: an updated meta-analysis comparing midterm outcomes. Catheter Cardiovasc Interv 2021;97:1481-8.
11. Saleem S, Ullah W, Syed MA, et al. Meta-analysis comparing valve-in-valve TAVR and redo-SAVR in patients with degenerated bioprosthetic aortic valve. Catheter Cardiovasc Interv 2021;98:940-7.
12. Tarantini G, Dvir D, Tang GHL. Transcatheter aortic valve implantation in degenerated surgical aortic valves. EuroIntervention 2021;17:709-19.
13. Edelman JJ, Khan JM, Rogers T, et al. Valve-in-valve TAVR: state-of-the-art review. Innovations (Phila) 2019;14:299-310.
14. Simonato M, Dvir D. Transcatheter aortic valve replacement in failed surgical valves. Heart 2019;105:s38-43.
15. Duncan A, Moat N, Simonato M, et al. Outcomes following transcatheter aortic valve replacement for degenerative stentless versus stented bioprostheses. JACC Cardiovasc Interv 2019;12:1256-63.
16. Ribeiro HB, Rodés-Cabau J, Blanke P, et al. Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. Eur Heart J 2018;39:687-95.
17. Alnasser S, Cheema AN, Simonato M, et al. Valve-in-Valve International Data Registry Investigators. Matched comparison of self-expanding transcatheter heart valves for the treatment of failed aortic surgical bioprosthesis: insights from the valve-in-valve international data registry (VIVID). Circ Cardiovasc Interv 2017;10:e004392.
18. Seiffert M, Treede H, Schofer J, et al. Matched comparison of next- and early-generation balloon-expandable transcatheter heart valve implantations in failed surgical aortic bioprostheses. EuroIntervention 2018;14:e397-404.
19. Francone M, Budde RPJ, Bremerich J, et al. CT and MR imaging prior to transcatheter aortic valve implantation: standardisation of scanning protocols, measurements and reporting-a consensus document by the European Society of Cardiovascular Radiology (ESCR). Eur Radiol 2020;30:2627-50.
20. Bapat V. Valve-in-valve apps: why and how they were developed and how to use them. EuroIntervention 2014;10 Suppl U:U44-51.
21. Jabbour RJ, Tanaka A, Finkelstein A, et al. Delayed coronary obstruction after transcatheter aortic valve replacement. J Am Coll Cardiol 2018;71:1513-24.
22. Dvir D. Treatment of small surgical valves: clinical considerations for achieving optimal results in valve-in-valve procedures. JACC Cardiovasc Interv 2015;8:2034-6.
23. Rodés-Cabau J, Pibarot P, Suri RM, et al. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: insights from the PARTNER Trial. Circ Cardiovasc Interv 2014;7:701-11.
24. Ochiai T, Oakley L, Sekhon N, et al. Risk of coronary obstruction due to sinus sequestration in redo transcatheter aortic valve replacement. JACC Cardiovasc Interv 2020;13:2617-27.
25. Blanke P, Soon J, Dvir D, et al. Computed tomography assessment for transcatheter aortic valve in valve implantation: the vancouver approach to predict anatomical risk for coronary obstruction and other considerations. J Cardiovasc Comput Tomogr 2016;10:491-9.
26. Dvir D, Leipsic J, Blanke P, et al. Coronary obstruction in transcatheter aortic valve-in-valve implantation: preprocedural evaluation, device selection, protection, and treatment. Circ Cardiovasc Interv 2015;8:e002079.
27. Mercanti F, Rosseel L, Neylon A, et al. Chimney stenting for coronary occlusion during TAVR: insights from the chimney registry. JACC Cardiovasc Interv 2020;13:751-61.
28. Romano V, Buzzatti N, Latib A, Colombo A, Montorfano M. Chimney technique for coronary obstruction after aortic valve in valve: pros and cons. Eur Heart J Cardiovasc Imaging 2018;19:1194.
29. Khan JM, Dvir D, Greenbaum AB, et al. Transcatheter laceration of aortic leaflets to prevent coronary obstruction during transcatheter aortic valve replacement: concept to first-in-human. JACC Cardiovasc Interv 2018;11:677-89.
30. Khan JM, Greenbaum AB, Babaliaros VC, et al. The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction. JACC Cardiovasc Interv 2019;12:1240-52.
31. De Backer O, Søndergaard L. Is BASILICA the standard for preventing coronary obstruction in high-risk transcatheter aortic valve replacement? JACC Cardiovasc Interv 2021;14:949-51.
32. Khan JM, Babaliaros VC, Greenbaum AB, et al. Preventing coronary obstruction during transcatheter aortic valve replacement: results from the multicenter international BASILICA registry. JACC Cardiovasc Interv 2021;14:941-8.
33. Tarantini G, Fabris T, Nai Fovino L. TAVR-in-TAVR and coronary access: importance of preprocedural planning. EuroIntervention 2020;16:e129-32.
34. Nai Fovino L, Scotti A, Massussi M, et al. Coronary angiography after transcatheter aortic valve replacement (TAVR) to evaluate the risk of coronary access impairment after TAVR-in-TAVR. J Am Heart Assoc 2020;9:e016446.
35. Tang GHL, Zaid S, Gupta E, et al. Feasibility of repeat tavr after SAPIEN 3 TAVR: a novel classification scheme and pilot angiographic study. JACC Cardiovasc Interv 2019;12:1290-2.
36. Akodad M, Sellers S, Gulsin GS, et al. Leaflet and neoskirt height in transcatheter heart valves: implications for repeat procedures and coronary access. JACC Cardiovasc Interv 2021;14:2298-300.
37. Tang GHL, Komatsu I, Tzemach L, et al. Risk of coronary obstruction and the need to perform BASILICA: the VIVID classification. EuroIntervention 2020;16:e757-9.
38. Tarantini G, Fabris T, Cardaioli F, Nai Fovino L. Coronary access after transcatheter aortic valve replacement in patients with bicuspid aortic valve: lights and shades. JACC Cardiovasc Interv 2019;12:1190-1.
39. De Backer O, Landes U, Fuchs A, et al. Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography. JACC Cardiovasc Interv 2020;13:2528-38.
40. Bilkhu R, Jahangiri M, Otto CM. Patient-prosthesis mismatch following aortic valve replacement. Heart 2019;105:s28-33.
41. Wendt D, Thielmann M, Plicht B, et al. The new St Jude Trifecta versus Carpentier-Edwards Perimount Magna and Magna Ease aortic bioprosthesis: is there a hemodynamic superiority? J Thorac Cardiovasc Surg 2014;147:1553-60.
42. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT registry. J Am Coll Cardiol 2018;72:2701-11.
43. Vemulapalli S, Holmes DR Jr, Dai D, et al. Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: a report from the STS/ACC TVT Registry. Am Heart J 2018;195:1-13.
44. Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts K, Meuris B. Prosthesis-patient mismatch predicts structural valve degeneration in bioprosthetic heart valves. Circulation 2010;121:2123-9.
45. Jie Yao R, Simonato M, Dvir D; Department of Cardiology, St Paul’s Hospital, Vancouver, Canada, Department of Cardiology, St Paul’s Hospital, Vancouver, Canada, Department of Cardiology, St Paul’s Hospital, Vancouver, Canada. Optimising the haemodynamics of aortic valve-in-valve procedures. Interv Cardiol 2017;12:40.
46. Pibarot P, Simonato M, Barbanti M, et al. Impact of pre-existing prosthesis-patient mismatch on survival following aortic valve-in-valve procedures. JACC Cardiovasc Interv 2018;11:133-41.
47. Jilaihawi H, Chin D, Spyt T, et al. Prosthesis-patient mismatch after transcatheter aortic valve implantation with the Medtronic-Corevalve bioprosthesis. Eur Heart J 2010;31:857-64.
48. Simonato M, Webb J, Bleiziffer S, et al. Current generation balloon-expandable transcatheter valve positioning strategies during aortic valve-in-valve procedures and clinical outcomes. JACC Cardiovasc Interv 2019;12:1606-17.
49. Simonato M, Azadani AN, Webb J, et al. In vitro evaluation of implantation depth in valve-in-valve using different transcatheter heart valves. EuroIntervention 2016;12:909-17.
50. Azadani AN, Reardon M, Simonato M, et al. Effect of transcatheter aortic valve size and position on valve-in-valve hemodynamics: an in vitro study. J Thorac Cardiovasc Surg 2017;153:1303-15.e1.
51. Zenses AS, Evin MA, Stanová V, et al. Effect of size and position of self-expanding transcatheter valve on haemodynamics following valve-in-valve procedure in small surgical bioprostheses: an in vitro study. EuroIntervention 2018;14:e282-9.
52. Dvir D, Khan J, Kornowski R, et al. Novel strategies in aortic valve-in-valve therapy including bioprosthetic valve fracture and BASILICA. EuroIntervention 2018;14:AB74-82.
53. Grubitzsch H, Galloni M, Falk V. Wrinkles, folds and calcifications: reduced durability after transcatheter aortic valve-in-valve replacement. J Thorac Cardiovasc Surg 2017;153:266-8.
54. Allen KB, Chhatriwalla AK, Cohen DJ, et al. Bioprosthetic valve fracture to facilitate transcatheter valve-in-valve implantation. Ann Thorac Surg 2017;104:1501-8.
55. Saxon JT, Allen KB, Cohen DJ, Chhatriwalla AK. Bioprosthetic valve fracture during valve-in-valve TAVR: bench to bedside. Interv Cardiol 2018;13:20-6.
56. Chhatriwalla AK, Allen KB, Saxon JT, et al. Bioprosthetic valve fracture improves the hemodynamic results of valve-in-valve transcatheter aortic valve replacement. Circ Cardiovasc Interv 2017;10:e005216.
57. Ziccardi MR, Groves EM. Bioprosthetic valve fracture for valve-in-valve transcatheter aortic valve replacement: rationale, patient selection, technique, and outcomes. Interv Cardiol Clin 2019;8:373-82.
58. Nielsen-Kudsk JE, Andersen A, Therkelsen CJ, et al. High-pressure balloon fracturing of small dysfunctional Mitroflow bioprostheses facilitates transcatheter aortic valve-in-valve implantation. EuroIntervention 2017;13:e1020-5.
59. Patel JS, Krishnaswamy A, White J, et al. Optimizing hemodynamics of transcatheter aortic valve-in-valve implantation in 19-mm surgical aortic prostheses. Catheter Cardiovasc Interv 2018;92:550-4.
60. Tamagnini G, Bourguignon T, Rega F, et al. Device profile of the Inspiris Resilia valve for aortic valve replacement: overview of its safety and efficacy. Expert Rev Med Devices 2021;18:239-44.
61. Okamoto Y, Yamamoto K, Sugimoto T, Yoshii S. Early and late outcomes of AVR with aortic annular enlargement in octogenarian. Gen Thorac Cardiovasc Surg 2015;63:453-8.
62. Mack MJ, Leon MB, Thourani VH, et al. PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.
63. Popma JJ, Deeb GM, Yakubov SJ, et al. Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706-15.
64. Tarantini G, Nai Fovino L. Lifetime strategy of patients with aortic stenosis: the first cut is the deepest. JACC Cardiovasc Interv 2021;14:1727-30.
65. Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv 2020;13:e008972.
66. Bapat VN, Zaid S, Fukuhara S, et al. EXPLANT-TAVR Investigators. Surgical explantation after TAVR failure: Mid-term outcomes from the EXPLANT-TAVR international registry. JACC Cardiovasc Interv 2021;14:1978-91.
67. Fukuhara S, Brescia AA, Shiomi S, et al. Surgical explantation of transcatheter aortic bioprostheses: results and clinical implications. J Thorac Cardiovasc Surg 2021;162:539-47.e1.
68. Percy ED, Harloff MT, Hirji S, et al. Nationally representative repeat transcatheter aortic valve replacement outcomes: report from the centers for medicare and medicaid services. JACC Cardiovasc Interv 2021;14:1717-26.
69. Hirji SA, Percy ED, McGurk S, et al. Incidence, characteristics, predictors, and outcomes of surgical explantation after transcatheter aortic valve replacement. J Am Coll Cardiol 2020;76:1848-59.
70. Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol 2020;75:1882-93.
71. Attizzani GF, Ohno Y, Latib A, et al. Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: a multicenter study. Int J Cardiol 2017;227:543-9.
72. Barbanti M, Webb JG, Tamburino C, et al. Outcomes of redo transcatheter aortic valve replacement for the treatment of postprocedural and late occurrence of paravalvular regurgitation and transcatheter valve failure. Circ Cardiovasc Interv 2016;9:e003930.
73. Barbanti M, Costa G, Picci A, et al. Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC Cardiovasc Interv 2020;13:2542-55.
74. Bleiziffer S, Simonato M, Webb JG, et al. Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. Eur Heart J 2020;41:2731-42.
75. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017;389:2383-92.
76. Blanke P, Leipsic JA, Popma JJ, et al. Evolut Low Risk LTI Substudy Investigators. Bioprosthetic aortic valve leaflet thickening in the evolut low risk sub-study. J Am Coll Cardiol 2020;75:2430-42.
77. De Backer O, Dangas GD, Jilaihawi H, et al; GALILEO-4D Investigators. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med 2020;382:130-9.
78. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 2015;373:2015-24.
79. Dangas GD, Tijssen JGP, Wöhrle J, et al. GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020;382:120-9.
80. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without Clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:1696-707.
81. Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without Clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;383:1447-57.
82. Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol 2020;75:3003-15.
83. Abdel-Wahab M, Simonato M, Latib A, et al. Clinical valve thrombosis after transcatheter aortic valve-in-valve implantation. Circ Cardiovasc Interv 2018;11:e006730.
84. Ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J 2021;42:2265-9.
85. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement: incidence, characteristics, and treatment outcomes. JACC Cardiovasc Interv 2017;10:686-97.
86. Vahidkhah K, Javani S, Abbasi M, et al. Blood stasis on transcatheter valve leaflets and implications for valve-in-valve leaflet thrombosis. Ann Thorac Surg 2017;104:751-9.
87. Brown ML, Park SJ, Sundt TM, Schaff HV. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg 2012;144:108-11.
88. Eggebrecht H, Schmermund A, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 2012;8:129-38.
89. Eitan A, Brinkmann C, Haselbach T, Witt J, Schofer J. Does valve in valve TAVR carry a higher risk for thromboembolic events compared to native valve TAVR? Catheter Cardiovasc Interv 2020;95:1017-21.
90. Macherey S, Meertens M, Mauri V, et al. Meta-analysis of stroke and mortality rates in patients undergoing valve-in-valve transcatheter aortic valve replacement. J Am Heart Assoc 2021;10:e019512.
91. Lansky AJ, Schofer J, Tchetche D, et al. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J 2015;36:2070-8.
92. Kapadia SR, Kodali S, Makkar R, et al. SENTINEL Trial Investigators. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol 2017;69:367-77.
